Taxen-based chemotherapy has been established as an effective treatment option in castration-resistant metastatic prostate cancer (mCRPC). Randomized phaseIII studies, however, have shown that even in the hormone-nave metastatic state, the early use of chemotherapy in addition to the classical androgen...
doi:10.1038/nrurol.2013.232Grivas, Petros D.Keller, Evan T.Nature Reviews UrologyPetros D.Grivas, Evan T.Keller. (2013) Prostate cancer: Radium-223: a new treatment option for bone-metastatic CRPC. Nature Reviews Urology 10 , 630-631 /...
levels and other significant improvements in a stage 4 prostatecancer patient, who sought precision oncology treatment at envita. disclaimer: individual results will vary. envita makes no guarantees for outcomes. each patient case is unique. pleaseconsult your doctor before making any changes to your...
Patients who want to finish their treatment quickly may prefer docetaxel, said Morris. The second consideration is financial, "depending on the healthcare system in which you are receiving your care." He explained: "For patients who don't have drug coverage, the chemotherapy option could be qui...
Sipuleucel-T in the treatment of prostate cancer: An evidence-based review of its place in therapy Metastatic castration-resistant prostate cancer is the lethal form of cancer of the prostate. Five new agents that prolong survival in this group have emerged in the past 5 years, and sipuleucel-...
Therapy With Metronomic Cyclophosphamide (mCyc) for Previously-Treated Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Despite introduction of various novel therapies, treatment options for metastatic castrate resistant prostate cancer (mCRPC) remain limited. This is a retr......
In the past decade, a revolution in the treatment of metastatic prostate cancer has occurred with the advent of novel hormonal agents and life-prolonging chemotherapy regimens in combination with standard androgen-deprivation therapy. Notwithstanding, th
TRUS and biopsy revealed adenocarcinoma of the prostate gland, Gleason score 8 [4+4] with disease in 10/12 cores. PSA 150 ng/mL; Hb 9.7 g/dL; ANC 1.9 Liver function tests are abnormal Initial Diagnosis and Treatment Patient is diagnosed with localized prostate cancer ...
The trial established cabazitaxel as a tolerable and viable second line treatment option in these patients. We report our experience with cabazitaxel in patients receiving treatment within the Early Access Programme (EAP) and via the Cancer Drugs Fund (CDF). Retrospective review of patients receiving...
OBJECTIVE: To evaluate the efficacy of enzalutamide (Enz) as fourth- or fifth-line treatment in men with metastasized castration-resistant prostate cancer (mCRPC), by analyzing a retrospective cohort of heavily pretreated patients. METHODS: We evaluated toxicity, overall survival (OS), progression-fre...